Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - Still a Buy?

Key Points

• Zealand Pharma A/S shares gapped up on Monday, opening at $61.77 after a previous close of $57.50, and last traded at $61.00 with a trading volume of 1,630 shares.
• Brokerages have upgraded Zealand Pharma A/S to a "strong-buy" rating, resulting in an average rating of "Strong Buy" from analysts, with one analyst giving a buy rating and five recommending a strong buy.
• The company reported a quarterly earnings per share (EPS) of $16.06, which was below the consensus estimate of $16.72, along with revenue significantly missing expectations at $1.43 billion compared to a forecast of $9.18 billion.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $57.50, but opened at $61.77. Zealand Pharma A/S shares last traded at $61.00, with a volume of 1,630 shares changing hands.

Analyst Ratings Changes

Several brokerages have recently commented on ZLDPF. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Thursday, July 24th. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Finally, Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a report on Monday, July 7th. One analyst has rated the stock with a buy rating and five have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Strong Buy".

Zealand Pharma A/S Price Performance

The stock has a market capitalization of $4.33 billion, a P/E ratio of 4.28 and a beta of 0.71. The company has a debt-to-equity ratio of 0.03, a quick ratio of 25.07 and a current ratio of 25.10. The stock has a 50-day simple moving average of $58.06 and a 200 day simple moving average of $70.69.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $16.72 by ($0.66). The firm had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 82.30%. On average, equities analysts forecast that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.